SELADELPAR



NAME OF DRUG : SELADELPAR

ALSO KNOWN AS : MBX_8025

LABORATORY : CYMABAY_THERAPEUTICS

STATUS AND ADVANCEMENT

Type of drug : PPAR delta receptor agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated time to market : 101 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON SELADELPAR

2020-03-12 : CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update

2019-11-25 : CymaBay Therapeutics Halts Clinical Development of Seladelpar

2019-02-15 : CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis

SOME PUBLICATIONS RELATED WITH SELADELPAR

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH SELADELPAR


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE